

# Molecular and Cellular Biomedical Sciences

Volume 2, Number 1, March 2018

## REVIEW ARTICLES

**Naïve T Cells in Immunosuppression Diseases: Human Immunodeficiency Virus and Cytomegalovirus**

*Kent Wijaya Setiawan, Ferry Sandra; p.1-10*

**Dental Osteoclastogenesis in Periodontitis: Signaling Pathway, Synthetic and Natural Inhibitors**

*Ketherin, Ferry Sandra; p.11-8*

**Role of Herbal Extract in Stem Cell Development**

*Ferry Sandra; p.19-22*

## RESEARCH ARTICLES

**Angiogenesis Intensity within Benign and Malignant Oral Mucosa Epithelial Tumor**

*Janti Sudiono, Sofia Thalib; p.23-7*

**Enucleation Induces Parvalbumin and Glial Fibrillary Acidic Protein, but Not Calbindin D28k Protein Expression in Superior Colliculus of Wistar Rats**

*Daniel Gonzalez, Szeifoul Afadlal, Kristin Lizal, Yulius Hermanto, Takanori Miki, Yoshiki Takeuchi, Irawan Satriotomo; p.28-37*

Print ISSN: 2527-4384

Online ISSN: 2527-3442

[www.CellBioPharm.com/ojs](http://www.CellBioPharm.com/ojs)

Cell and  
Biopharmaceutical  
Institute



# Molecular and Cellular Biomedical Sciences

## MAILING ADDRESS

MCBS OFFICE  
Jl. Raya Kelapa Sawit Ruko Sektor IE Blok BD.12 No.14  
Gading Serpong, Tangerang.  
Email: mcbs\_office@cellbiopharm.com

## PRINCIPAL CONTACT

Dr. Marshel Tendean  
Phone: +62-81285043419  
Email: dr.mars.23@gmail.com

## SUPPORT CONTACT

Dr. Allen Weber  
Email: mcbs\_office@cellbiopharm.com

## EDITOR IN CHIEF

Dr. Marshel Tendean  
Department of Internal Medicine, Faculty of Medicine,  
Krida Wacana Christian University, Indonesia

## EDITORIAL BOARD

Prof. Akihiro Shimosaka  
Hematology Institute, Peking Union Medical College, China

Prof. Anak Iamaroon  
Department of Oral Biology and Diagnostic Sciences,  
Faculty of Dentistry, Chiang Mai University, Thailand

Dr. Bin Ren  
Division of Hematology and Oncology, Department of Medicine,  
Medical College of Wisconsin, United States of America

Prof. Hee Young Shin  
Department of Pediatrics, Cancer Research Institute,  
Seoul National University College of Medicine, South Korea

Prof. Hiroyuki Kumamoto  
Division of Oral Pathology, Department of Oral Medicine and Surgery,  
Graduate School of Dentistry, Tohoku University, Japan

Dr. Ines Atmosukarto  
College of Medicine, Biology & Environment,  
Australian National University, Australia

Dr. Irawan Satriotomo  
Center for Translational Research in Neurodegenerative Disease (CTRND),  
University of Florida, United States of America

Dr. Laifa Annisa Hendarmin  
Section of Biology, Faculty of Medicine and Health Sciences,  
Syarif Hidayatullah State Islamic University, Indonesia

Dr. Mutsumi Miyauchi  
Department of Oral and Maxillofacial Pathobiology, Basic Life Sciences,  
Institute of Biomedical and Health Sciences, Hiroshima University, Japan

Dr. Thai Yen Ling  
Department of Pharmacology,  
College of Medicine, National Taiwan University, Taiwan

Dr. Wahyu Widowati  
Department of Biology,  
Faculty of Medicine, Maranatha Christian University, Indonesia

Prof. Yen Hua Huang  
Department of Biochemistry and Molecular Cell Biology,  
Graduate Institute of Medical Sciences College of Medicine,  
Taipei Medical University, Taiwan

Dr. Yudi Her Oktaviono  
Department of Cardiology and Vascular Medicine,  
Faculty of Medicine / Dr. Soetomo Hospital, Airlangga University, Indonesia

## FOCUS AND SCOPE

Molecular and Cellular Biomedical Sciences (MCBS) is an open access, peer-reviewed journal that supports all topics in Biology, Pathology, Pharmacology, Biochemistry, Histology and Biomedicine in the aspect of molecular and cellular.

MCBS is dedicated to publish review and research articles. The editors will carefully select manuscript to be delivered for peer-reviewing process. Therefore MCBS is committed to present only the valuable and recent scientific findings.

## SECTION POLICIES

**REVIEW ARTICLE**  
Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

**RESEARCH ARTICLE**  
Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

## PEER REVIEW PROCESS

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be selected and blind peer-reviewed by 2 or more reviewers when necessary, to present valuable and authentic findings. All details will also be reviewed, including appropriate title; content reflecting abstract; concise writing; clear purpose, study method and figures and/or tables; and summary supported by content. The reviewing process will take generally 2-3 months depends on sufficiency of information provided.

Peer-reviewers were selected based on their specialties that fit to the topic. Additional reviewer/s can also be pointed when necessary. Author can suggest reviewer/s that not having publication together within five years and should not be member/s of the same research institution.

## PUBLICATION FREQUENCY

Molecular and Cellular Biomedical Sciences is published biannually (in March and September).

## OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

## ARCHIVING

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.

# Molecular and Cellular Biomedical Sciences

## PLAGIARISM SCREENING POLICY

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be screened for plagiarism by using Grammarly.

## CONTENT LICENSING

All materials are free to be copied and redistributed in any medium or format. However, appropriate credit should be given. The material may not be used for commercial purposes. This content licensing is in accordance with a CC license: CC-BY-NC

## CONFLICT OF INTEREST POLICY

### AUTHOR'S CONFLICT OF INTEREST

At the point of submission, Molecular and Cellular Biomedical Sciences requires that each author reveal any personal and/or financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated. When considering whether you should declare a conflicting interest or connection, please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it? Corresponding authors are responsible to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. The statement includes any information regarding whether the manuscript is under consideration for other publication, or whether you have any patents that relevant to the manuscript. If the manuscript is published, any conflict of interest information will be written in the Conflict of Interest statement.

### AUTHOR'S ACKNOWLEDGEMENT

Authors whose manuscripts are submitted for publication must declare all relevant sources of funding in support of the preparation of a manuscript. Molecular and Cellular Biomedical Sciences requires full disclosure of financial support as to whether it is from government agencies, the pharmaceutical or any other industry, or any other source. Authors are required to specify sources of funding for the study and to indicate whether or not the manuscript was reviewed by the sponsor prior to submission. This information should be included in the Acknowledgements section of the manuscript. In addition to disclosure of direct financial support to the authors or their laboratories and prior sponsor-review of the paper, corresponding authors will be asked to disclose all relevant consultancies since the views expressed in the contribution could be influenced by the opinions they have expressed privately as consultants. This information should also be included in the Acknowledgments section of the manuscript.

### REVIEWER'S CONFLICT OF INTEREST

Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and should recuse themselves from reviewing specific manuscripts if the potential for bias exists. As in the case of authors, silence on the part of reviewers concerning potential conflicts may mean either that such conflicts exist that they have failed to disclose, or that conflicts do not exist. Reviewers must not use information of the manuscript they are reviewing before it is being published, to further their own interests.

## PROTECTION OF HUMAN SUBJECT AND ANIMAL IN RESEARCH POLICY

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the said declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Further guidance on animal research ethics is available from the International Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and Welfare.

## INFORMED CONSENT POLICY

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Authors should disclose to these patients whether any potential identifiable material might be available via internet as well as in print after publication. Nonessential identifying details should be omitted.

Molecular and Cellular Biomedical Sciences decides that patient confidentiality is better guarded by having the authors archive the consent, and instead providing us with a written statement in the manuscript attesting that they have received and archived written patient consent. When informed consent has been obtained, it should be indicated later in the published article.

## ROLE OF JOURNAL EDITOR

Editors of Molecular and Cellular Biomedical Sciences have responsibilities toward the authors who provide the content of the journals, the peer reviewers who comment on the suitability of manuscripts for publication, also toward the journal's readers and the scientific community. Editors are responsible for monitoring and ensuring the fairness, timeliness, thoroughness, and civility of the peer-review and other editorial processes.

Peer review by external reviewers with the proper expertise is the most common method to ensure manuscript quality. However, our editors may sometimes reject manuscripts without external peer review to make the best use of their resources. Reasons for this practice are usually that the manuscript is outside the scope of Molecular and Cellular Biomedical Sciences, does not meet our quality standards or lacks originality or novel information.

### Editor Responsibilities toward Authors

- Providing guidelines to authors for preparing and submitting manuscripts
- Providing a clear statement of the Journal's policies on authorship criteria
- Treating all authors with fairness, courtesy, objectivity, honesty, and transparency
- Establishing and defining policies on conflicts of interest for all involved in the publication process, including editors, staff, authors, and reviewers
- Protecting the confidentiality of every author's work
- Establishing a system for effective and rapid peer review
- Making editorial decisions with reasonable speed and communicating them in a clear and constructive manner
- Being vigilant in avoiding the possibility of editors and/or referees delaying a manuscript for suspect reasons
- Establishing a procedure for reconsidering editorial decisions
- Describing, implementing, and regularly reviewing policies for handling ethical issues and allegations or findings of misconduct by authors and anyone involved in the peer review process
- Informing authors of solicited manuscripts that the submission will be evaluated according to the journal's standard procedures or outlining the decision-making process if it differs from those procedures
- Clearly communicating all other editorial policies and standards

### Editor Responsibilities toward Reviewers

- Assigning papers for review appropriate to each reviewer's area of interest and expertise
- Establishing a process for reviewers to ensure that they treat the manuscript as a confidential document and complete the review promptly
- Informing reviewers that they are not allowed to make any use of the work described in the manuscript or to take advantage of the knowledge they gained by reviewing it before publication
- Providing reviewers with written, explicit instructions on the journal's expectations for the scope, content, quality, and timeliness of their reviews to promote thoughtful, fair, constructive, and informative critique of the submitted work
- Requesting that reviewers identify any potential conflicts of interest and asking that they recuse themselves if they cannot provide an unbiased review
- Allowing reviewers appropriate time to complete their reviews
- Requesting reviews at a reasonable frequency that does not overtask any reviewer

# Molecular and Cellular Biomedical Sciences

- Finding ways to recognize the contributions of reviewers, for example, by publicly thanking them in the journal; providing letters that might be used in applications for academic promotion; offering professional education credits; or inviting them to serve on the editorial board of the journal
- Making final decision regarding a submission status after receiving review result from reviewers

## Editor Responsibilities toward Readers and the Scientific Community

- Evaluating all manuscripts considered for publication to make certain that each provides the evidence readers need to evaluate the authors' conclusions and that authors' conclusions reflect the evidence provided in the manuscript
- Providing literature references and author contact information so interested readers may pursue further discourse
- Requiring the corresponding author to review and accept responsibility for the content of the final draft of each paper
- Maintaining the journal's internal integrity (e.g., correcting errors; clearly identifying and differentiating types of content, such as reports of original data, corrections/errata, retractions, supplemental data, and promotional material or advertising; and identifying published material with proper references)
- Ensuring that all involved in the publication process understand that it is inappropriate to manipulate citations by, for example, demanding that authors cite papers in the journal
- Disclosing all relevant potential conflicts of interest of those involved in considering a manuscript or affirming that none exist
- Working with the publisher to attract the best manuscripts and research that will be of interest to readers

## AUTHOR GUIDELINES

### 1. General Terms

Molecular and Cellular Biomedical Sciences welcomes articles covering all aspects of biomedical sciences. All submitted manuscripts must not be previously published and not under consideration for publication elsewhere. Papers may come from any country but must be written in English. The manuscript may be submitted as review articles, research articles, and short communications. There are no submission and processing charges for this journal.

All manuscripts are subjected to peer review. All submissions must be accompanied by abstracts of the authors' manuscripts on related subjects that are in press or under editorial review. Electronic reprints of related published papers by the author/s or manuscripts in the press also may be helpful to the reviewers.

All manuscripts must be accompanied by a covering letter signed by all author/s. Upon acceptance, author/s must transfer copyright to Cell and BioPharmaceutical Institute (CBPI). Accepted papers become the permanent property of CBPI and may be used according to copyright policy, or for particular purposes, please contact CBPI. It is the author/s' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publication.

### 2. How to Submit

Authors are required to submit manuscripts electronically by using online journal system [cellbiopharm.com/ojs](http://cellbiopharm.com/ojs).

### 3. Requirements of Each Manuscript Type

**Review Article:** Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

**Research Article:** Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

### 4. Abstract

Provide an abstract of no more than 300 words (for Review Article) or 250 words (for Research Article). Structured-abstract should be followed in writing Research Article.

### 5. References

- References should be according to the Vancouver system.
- List all authors when there are six or fewer; when there are seven or more, list the first six, followed by "et al."
- A sequential number of references in the main text. Please follow in detail all examples below:

#### Article:

Sandra F, Esposti MD, Ndebele K, Gona P, Knight D, Rosenquist M, et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids. *Cancer Res.* 2005; 65(18): 8286-97.

#### Book

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.

#### Chapter in a book:

Rosenberg GA. Matrix metalloproteinase and proteolytic opening of the blood-brain-barrier in neuroinflammation. In: deVries E, Prat A, editors. *The Blood-brain Barrier and Its Microenvironment Basic Physiology To Neurological Disease*. New York: Taylor and Francis Group; 2005. p.335-58.

#### Dissertation/Thesis/Essay:

Arlaukas SP. Near infrared fluorescent choline kinase alpha inhibitors for cancer imaging and therapy [Dissertation]. Philadelphia: University of Pennsylvania; 2015.

#### Part of Website/Monograph:

Medline Plus [Internet]. Bethesda: US National Library of Medicine; ©2009. Diabetic Kidney Problems [update 2015 Nov 2; cited 2015 Nov 16]. Available from: <https://www.nlm.nih.gov/medlineplus/diabetickidneyproblems.html>.

#### Conference Paper:

Fledelius HS. Myopia and significant visual impairment: global aspects. In: Lin LLK, Shin YF, Hung PT, editors. *Myopia Updates II: Proceedings of the 7th International Conference on Myopia 1998 Nov 17-20, Taipei*. Tokyo: Springer; 2000. p.3-17.

### 6. Unit of Measurement

- Authors can express all measurements in Conventional or International System (SI) units.
- Drug names must use generic names. When proprietary brands are used in research, include the brand name, the name and location (city & country) of the manufacturer in parentheses after the first mention of the generic name.

## SUBMISSION PREPARATION CHECKLIST

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format. Formatted as standard A4 page setup.
3. Where available, URLs for the references have been provided.
4. The text should be double-spaced with the 1-inch margin on the left and right sides. Use 12-point Times New Roman font.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. Running title provided (not more than 8 words).
7. Proof of permission was obtained to reproduce illustrations, tables, etc. from other publication.
8. Complete information about author/s (first, middle, last name), author/s affiliation, and email address of the corresponding author.
9. All pages are numbered at bottom right.

## COPYRIGHT NOTICE

For the submission of a manuscript to Molecular and Cellular Biomedical Sciences, I hereby certify that:

1. I have been granted authorization by my co-author/s to enter into these arrangements.
2. I hereby declare, on behalf of myself and my co-author/s, that:
  - The manuscript submitted is an original work and has neither been published in any other peer-reviewed journal nor is under consideration for publication by any other journal. More so, the work has been carried out in the author/s' lab and the manuscript does not contravene any existing copyright or any other third party rights.

# Molecular and Cellular Biomedical Sciences

- I am/we are the sole author/s of the manuscript and maintain the authority to enter into this agreement and the granting of rights to the publisher: The Cell and BioPharmaceutical Institute (CBPI), does not infringe any clause of this agreement.
- The manuscript contains no such material that may be unlawful, defamatory, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the agreement.
- I/we have taken due care that the scientific knowledge and all other statements contained in the manuscript conform to true facts and authentic formulae and will not, if followed precisely, be detrimental to the user.
- I/we permit the adaptation, preparation of derivative works, oral presentation or distribution, along with the commercial application of the work.
- No responsibility is assumed by Molecular and Cellular Biomedical Sciences (MCBS) and CBPI, its staff or members of the editorial boards for any injury and/or damage to persons or property as a matter of

products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in a publication by MCBS.

**Copyright:**

Author/s who publish in any MCBS print & online journal will transfer copyright to their work to CBPI. Submission of a manuscript to the respective journals implies that all author/s have read and agreed to the content of the Covering Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the manuscript for publication the author/s agree that the publishers have the legal right to take appropriate action against the author/s, if plagiarism or fabricated information is discovered. By submitting a manuscript, the author/s agree that the copyright of their manuscript is transferred to CBPI, if and when the manuscript is accepted for publication. Once submitted to the journal, the author/s will not withdraw their manuscript at any stage prior to publication. However, the copyright will be released to author/s when the manuscript is rejected.

# Molecular and Cellular Biomedical Sciences

## CONTENT

### REVIEW ARTICLES

**Naïve T Cells in Immunosuppression Diseases: Human Immunodeficiency Virus and Cytomegalovirus**

*Kent Wijaya Setiawan, Ferry Sandra*

*p.1-10*

**Dental Osteoclastogenesis in Periodontitis: Signaling Pathway, Synthetic and Natural Inhibitors**

*Ketherin, Ferry Sandra*

*p.11-8*

**Role of Herbal Extract in Stem Cell Development**

*Ferry Sandra*

*p.19-22*

### RESEARCH ARTICLES

**Angiogenesis Intensity within Benign and Malignant Oral Mucosa Epithelial Tumor**

*Janti Sudiono, Sofia Thalib*

*p.23-7*

**Enucleation Induces Parvalbumin and Glial Fibrillary Acidic Protein, but Not Calbindin D28k Protein Expression in Superior Colliculus of Wistar Rats**

*Daniel Gonzalez, Szeifoul Afadlal, Kristin Lizal, Yulius Hermanto, Takanori Miki, Yoshiki Takeuchi,*

*Irawan Satriotomo*

*p.28-37*

## REVIEW ARTICLE

MCBS

Mol Cell Biomed Sci. 2018; 2(1): 11-8  
DOI: 10.21705/mcbs.v2i1.16

# Osteoclastogenesis in Periodontitis: Signaling Pathway, Synthetic and Natural Inhibitors

Ketherin<sup>1</sup>, Ferry Sandra<sup>2,3</sup><sup>1</sup>Faculty of Dentistry, Trisakti University, Jakarta, Indonesia<sup>2</sup>Department of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Trisakti University, Jakarta, Indonesia<sup>3</sup>BioCORE Laboratory, Faculty of Dentistry, Trisakti University, Jakarta, Indonesia

Osteoclast activities are responsible for the resorption of bone cells found in several bone diseases, one of which is periodontitis and arthritis. The upregulating signals of Receptor Activator of Nuclear Factor  $\kappa$ B (RANK)-RANK Ligand and Tumor Necrosis Factor (TNF)- $\alpha$  are the major cause of the bone destruction. Studies and experiments have been performed to overcome this matter. Various medications are now available to treat bone-related diseases, targeting the specific aspect of the signaling. Synthetic drugs such as denosumab and bisphosphonates have complex pharmacological action and have been the leading choice in treatment. Evidence in studies proved that natural resources including herbal products have potential application to therapy for bone loss, with caffeic acid and Caffeic Acid Phenethyl Ester (CAPE) showing significant inhibitory results and Chinese herbs such as *Herba epimedii* (Yín Yáng Huò) and *Fructus psoraleae* (Bǔ Gǔ Zhī) proved to contain components that give similar effects to estrogen. The purpose of this review is to discuss the therapy value of available synthetic and natural therapeutic agents. Understanding the mechanisms of both agents will not only clarify their function as therapeutic agents, but can also be the key to the treatment of diseases caused by bone resorption by targeting specific aspects of osteoclastogenesis.

**Keywords:** osteoclastogenesis, TNF, RANKL, bone resorption, natural resource, signaling, treatment

## Introduction

The bone loss progression seen in periodontitis is a result of excessive cytokine production, one of which is Receptor Activator of Nuclear Factor  $\kappa$ B (RANK) Ligand (RANKL). RANK and RANKL signaling plays a prominent role in osteoclastogenesis, producing osteoclast cells. The binding of RANK-RANKL signaling induces Tumor Necrosis Factor (TNF) Receptor Associated Factor (TRAF) 6 and further leads to activation of its cascades such as

Extracellular Signal-Regulated Kinase (ERK), Janus N-terminal Kinase (JNK), Nuclear Factor  $\kappa$ B (NF $\kappa$ B), and p38 Mitogen-activated Protein Kinase (MAPK).<sup>1</sup> The p38 MAPK has important roles in cell's homeostasis such as cell proliferation, differentiation, maturation, apoptosis, and cytokine production, which makes p38 MAPK one of the key factors in osteoimmunology.<sup>2</sup> Therefore a therapeutic agent is needed to subdue this problem, and there is now evidence showing that not only synthetic medications but natural products can influence by inhibiting bone resorption

Date of submission: May 7, 2017

Accepted for publication: May 29, 2017

**Corresponding Author:**

Ferry Sandra

Department of Biochemistry and Molecular Biology, Division of Oral Biology  
Faculty of Dentistry, Trisakti University, Jl. Kyai Tapa No.260  
Jakarta, Indonesia

E-mail: ferrysandra@gmail.com



Cell and  
Biopharmaceutical  
Institute



process. Vegetables including onion, garlic, and parsley were reported to inhibit bone resorption in ovariectomized rats, while herbs like thyme, rosemary, and sage, increase bone mineral density.<sup>3</sup> Caffeic acid is a natural resource that has many uses as a therapeutic agent, one of which is to inhibit N-Nitrosation *in vitro* to inhibit the formation of mutagens and carcinogens. A study in 2011 showed that caffeic acid successfully suppresses osteoclastogenesis significantly by suppressing the activity NF $\kappa$ B.<sup>4</sup> Another natural source is *Stewartia koreana* was reported to suppress osteoclast differentiation successfully.<sup>5</sup> Drugs developed from synthetic substances including Bisphosphonates, Denosumab, Methotrexate (MTX) and Risedronate were also reported to have positive effects as a therapeutic agent of bone resorption related diseases.<sup>6,7</sup> This review aims to introduce therapeutic options available for bone resorption diseases. Understanding the options and mechanisms will not only clarify their function as therapeutic agents but can also be the key to the treatment of diseases caused by bone resorption.

## Periodontitis

Periodontitis defined by the American Academy of Periodontology as inflammation of the teeth supporting tissues that are usually characterized by progressive destructive changes that cause bone and periodontal ligament loss and an inflammatory response of the gingiva to the bone and ligaments adjacent.<sup>8</sup> This disease is an opportunistic infection caused by plaque. Plaque is a mass that mostly composed of microorganisms that stick to the teeth, prosthesis, and the surface of the mouth. The roles of plaque containing these microorganisms have been analyzed many years and are now introduced to the concept called osteoimmunology, which means researchers are focusing their study on the signaling system between the immune system and bone cells. In periodontal diseases, anaerobic bacteria and spirochetes grow in subgingival tissue then multiply into colonies and invade the host, generating irritation reactions and signs of inflammation. Extracts of *Aggregatibacter actinomycetemcomitans* has bacterial lipopolysaccharide (LPS) that induces a potent chemokine called interleukin (IL)-8. Induction of this chemokine will lead dendritic cells, neutrophils, macrophages, and lymphocytes to infiltrate the tissues and initiate the immune system. Stimulation of the bacteria then produces an inflammatory response in the form of excessive cytokine

formation, which will initiate and exacerbate periodontal diseases.<sup>1</sup>

The initial stage of infection begins with the activation of a mechanical shield that acts as a non-specific immune defense system leading to initial inflammatory response. B and T lymphocytes soon are activated when the bacteria begins to invade the tissues. A study states that the researchers are considering the T lymphocytes as an important bone regulator not only in periodontitis but also in other cases. T lymphocytes activate macrophages, indirectly activating the expression of osteoclast precursors and RANKL. Current knowledge shows that RANK/RANKL/Osteoprotegerin (OPG) signaling is involved in bone resorption process in patients suffering from periodontal disease. RANKL promotes bone resorption, while OPG inhibits bone resorption. Several studies were carried out to examine the levels of RANKL and OPG in patients with periodontitis. It was reported that patients with periodontitis had lower levels of OPG.<sup>10</sup> However, a study in ameloblastoma cell line showed that in a situation where OPG, TRAIL, and low level of RANKL present, OPG preferably binds to TRAIL, suppressing its ability to induce apoptosis in ameloblastoma. TRAIL has the highest apoptotic ability compared to TNF- $\alpha$  and RANKL, making the existence of OPG should be considered.<sup>10</sup> In addition to RANKL, TNF- $\alpha$  also plays an important role in inducing inflammation that exacerbates periodontitis.<sup>11</sup> Based on the data above, it is clear that pro-inflammatory mediators are the main cause of the increased severity of periodontal diseases and many of these cytokines are obtained from activated p38 MAPK whose activities depend on phosphorylation of tyrosine and threonine.<sup>1</sup>

## Osteoclastogenesis

Bone is a dynamic organ where it is constantly changing to reach its normal function called the bone remodeling process. Old bone cells will be degraded by the osteoclasts and replaced with new ones by osteoblasts. Therefore, the balance between bone formation and resorption process is vital to maintain bone's normal state.<sup>12</sup> Osteoclast is a multinucleated cell whose function is to resorb bone, derived from hematopoietic stem cells, and is made of myeloid progenitor cells involving fused mononuclear cells.<sup>4,13</sup> Osteoclast precursors undergo a series of differentiation stages resulting mature cells capable of destroying the bone.




Hematopoietic stem cells are divided into two major groups, common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP). Osteoclast comes from CMP, a bifurcation from monocyte/macrophage lineage while CLP induces lymphoid lineage cells such as T lymphocytes, B lymphocytes and other natural killer cells.<sup>15</sup> A study showed that osteoblastic cells are also required for osteoclast differentiation. Osteoblastic cells produce Macrophage Colony Stimulating Factor (M-CSF), even though M-CSF alone is not sufficient to induce osteoclastogenesis. M-CSF enhances the proliferation and survival of osteoclast precursors and helps the survival of mature osteoclast cells.<sup>14</sup>

### RANK-RANKL Signaling

The binding of RANK and RANKL is one of the major factors that affect osteoclastogenesis, proved in a study on mice. Osteopetrosis was seen in mice that had a shortage in RANK and RANKL induction.<sup>15</sup> RANKL is a member of the TNF superfamily, which is a protein found on the surface of mesenchymal osteoblast lineage, binding to its receptor, RANK, which will activate the osteoclast phenotype. Production of RANKL can be increased by parathyroid hormones that act as a stimulant agent of the osteoclast.<sup>16</sup> RANK does not have intrinsic enzyme

activity in its intracellular domain; it converts the energy to recruit adapter molecules such as proteins TRAF family to overcome this. TRAF is a cytoplasmic adapter protein that binds to the intracellular domain of various receptor of TNF receptor (TNFR).<sup>17</sup>

Among all TRAFs, TRAF 6 is the most important adapter for RANK-RANKL to induce osteoclastogenesis.<sup>18</sup> The relationship between TRAF6 and RANK will form a complex signaling, Transforming Growth Factor (TGF)- $\beta$ -activated kinase (TAK) 1 and TAK1-binding protein 2 which induce 3 MAPK signaling pathways such as ERK, p38 MAPK and JNK (Figure 1). The induction of TRAF6 in the RANK signaling is crucial in the phosphorylation process of RANK-induced NF $\kappa$ B.<sup>19</sup> TRAF 6 will continue the signals to NF $\kappa$ B, ERK, p38 MAPK, JNK, Akt, c-Fos, c-Src and Microphthalmia-inducing Transcription Factor (MITF).<sup>20,21</sup> RANKL induces Nuclear Factor of Activated T cells (NFATc)1 complex by inducing the expression of the c-Fos family and supporting c-Jun signaling.<sup>22</sup> NFATc1 regulates several osteoclast-specific genes, including the tartrate-resistant acid phosphatase, osteoclast-associated receptor and cathepsin K.<sup>22</sup> The important roles of NFATc1 in osteoclastogenesis have been studied with *in vitro* and *in vivo* tests carried out on mice. In *in vitro* studies, human embryonic stem cells that lack NFATc1 failed to differentiate into osteoclast, and *in vivo* observations, the



**Figure 1. RANK-RANKL osteoclastogenesis signaling pathway.** PIP2: phosphatidylinositol (4,5)-bisphosphate; PIP3: phosphatidylinositol (3,4,5)-trisphosphate; TAB: TAK1-binding protein; PDK: phosphoinositide-dependent protein kinase; IκB: Inhibitor of  $\kappa$ B; IKK: IκB kinase.

absence of NFATc1 in young mice would result in osteopetrosis proving that NFATc1 plays an important role on osteoclastogenesis.<sup>23</sup>

RANKL also activates Phosphoinositides 3-kinase (PI3K)/Akt through TRAF6, PI3K/Akt has a close relationship with Src kinase activity.<sup>24</sup> The absence of cellular Src kinase will inhibit phosphorylation of RANKL-induced Akt. Activated PI3K then creates phosphatidylinositol-(3,4,5)-phosphate in the plasma membrane, which then recruits Akt. PI3K inhibitor LY294002 was reported to inhibit osteoclast formation. The data above shows that the signaling of PI3K is involved in the differentiation process of the osteoclast.<sup>25</sup>

### TNF Signaling

While RANK-RANKL signaling is a major signaling in osteoclastogenesis, proinflammatory cytokines together with RANK and RANKL play an important role in osteoclast's differentiation and activation.<sup>26</sup> TNF- $\alpha$  also induces osteoclast formation *in vitro* by activating the NF $\kappa$ B and JNK. In fact, *in vitro* studies have hypothesized that TNF- $\alpha$  may induce osteoclastogenesis even when RANK-RANKL signaling is not present. TNF- $\alpha$  is formed by macrophages, monocytes and lymphocytes T. A study in mice showed an increased formation of osteoclast precursors in mice that had higher concentrations of TNF- $\alpha$ . TNF- $\alpha$  is part of TNF superfamily and plays an important role in various cell activities such as cell proliferation, differentiation, maintenance and apoptosis.<sup>27</sup> TNF- $\alpha$  induces paired Ig-like receptor-A (PIR-A), which is a co-stimulatory receptor for RANK to stimulate osteoclastogenesis.<sup>28</sup>

TNF- $\alpha$  also induces osteoclast precursor and marrow stromal cells that will express TNF receptor type 1 and produce proinflammatory cytokines, such as IL-1, RANKL and M-CSF. M-CSF then binds to c-fms, a tyrosine kinase receptor that induces osteoclast differentiation by activating ERK1/2 and PI3K/Akt giving direct impact on osteoclastogenesis.<sup>29</sup> Great recognition has been given towards TNF- $\alpha$  as numerous studies about anti-TNF treatment showed promising results in reducing bone erosions and inflammation.<sup>30,31</sup>

### M-CSF

Osteoblasts or the cells derived from new bones express 2 main cytokines contributing to osteoclast differentiation,

RANKL and M-CSF. Osteoclast precursors express M-CSF's receptor called c-Fms and RANK, which is RANKL's receptor. Their bindings play a major role in osteoclast differentiation.<sup>32</sup> M-CSF is a molecule that plays a big role in precursor's survival and proliferation. A study confirmed that op/op mice that failed to express functioning M-CSF are osteopetrosis. Another study mentioned mice lacking csf1r or the gene coding for c-Fms, experience a decrease in tissue macrophages and severe osteopetrosis confirming the evidence above.<sup>33</sup> The binding of M-CSF and c-fms has a complex downstream signals, however, to simplify it, M-CSF induces signaling in primary macrophages such as PI3K, p42/44 ERK, and c-Cbl. These are key transducers of M-CSF signaling.<sup>34</sup>

### Available Bone Resorption Inhibitor

The normal function of bone metabolism is deeply influenced by the balance of bone mineralization and resorption. However, the balance needed in maintaining bone's health is often compromised due to aging and bone related diseases. Thus, researchers have been studying prospecting materials to be developed as a potential therapy for bone related diseases.

### Synthetic Resources as Bone Resorption Inhibitor

Resorption inhibitor drugs have been the most common therapy when it comes to dealing with bone related diseases. Drugs can influence osteoclast's activity in many ways with their own biochemical mechanisms, many of which are created to help reduce bone resorption thus helping the healing process of the bone. Treatments have been varied from hormones such as estrogens and calcitonin to Denosumab which is an anti-RANKL antibody.<sup>35</sup>

#### *Bisphosphonates*

Bisphosphonates are potent bone resorption inhibitors and have been used as primary and therapeutic agents for bone related diseases such as osteogenesis imperfecta, heritable skeletal disorder in children, postmenopausal, glucocorticoid-induced osteoporosis, and bone metastases in malignancy cases. Bisphosphonates inhibit bone's calcification and hydroxyapatite breakdown making it an effective bone resorption inhibitor. Newer generations of bisphosphonates such as alendronate, risedronate, ibandronate, pamidronate,

and zoledronic acid have nitrogen in their chains by which promote osteoclast apoptosis more efficiently compared to non-nitrogen bisphosphonates.<sup>36</sup> Further study showed that alendronate and pamidronate inhibited osteoclastogenesis but did not target RANKL and OPG expression.<sup>37</sup> They inhibit farnesyl diphosphate synthase which is a cholesterol biosynthesis pathway enzyme, and by suppressing geranylgeranylation, osteoclast function is lost, and bone resorption progress is inhibited.<sup>38</sup> However, prolonged consumption of bisphosphonates may increase the potential for diseases such as osteonecrosis of the jaw, atypical fractures, and esophageal cancer.<sup>39</sup>

### ***Trichostatin A***

Trichostatin A is one of histone deacetylases inhibitor, which is an enzyme involved in the transcriptional activity and the remodeling of chromatin's structure. A study was conducted to analyze the effects of TSA on RANKL induced osteoclast formation and results showed a significant decrease of c-Fos and NFATc1 which play a big role in early osteoclastogenesis.<sup>40</sup> Further evidence showed TSA leads mature osteoclasts into apoptotic cell death thus making it a suitable candidate as a bone related therapeutic agent.<sup>41</sup> Lastly, TSA was reported to successfully inhibit osteoclast formation in co-culture of bone marrow cells and osteoblasts without reducing RANKL expression in osteoblasts. It was further explained that TSA suppressed RANKL-induced osteoclast formation from primary bone marrow-derived macrophages and only effective when present during the early stage of osteoclast differentiation.<sup>42</sup>

### ***Methotrexate***

Methotrexate is a folic acid inhibitor that binds to dihydrofolate reductase thus inhibiting the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).<sup>43</sup> Methotrexate is currently one of the most common therapies for rheumatoid arthritis patients. Rheumatoid arthritis is often characterized by synovial membrane inflammation and bone destruction, which can be measured by the increment of RANKL/OPG ratio. A study showed that Methotrexate decreased RANKL/OPG ratio and blocked M-CSF-RANKL induced osteoclastogenesis which makes Methotrexate a direct osteoclastogenesis inhibitor. Methotrexate is effective and safe, however, mucositis and oral ulceration can occur as side effects of the treatment, depending on the dosage. It

has also been reported that folate deficiency plays a role in predisposing mucositis induced by methotrexate. Due to this, supplementation with folinic acid has been proven effective to help fight the side effects of methotrexate without compromising its therapeutic action.<sup>44</sup>

### ***Denosumab***

Denosumab is a human monoclonal antibody that inhibits bone resorption by mimicking the effects of OPG thus inhibiting the binding of RANKL and RANK, a major signaling in osteoclastogenesis. Denosumab works by targeting RANKL specifically, making it unlikely to affect other regulatory systems.<sup>7</sup> A study was conducted to evaluate Denosumab's efficacy and safety, it was reported that Denosumab effectively increases the bone mass density (BMD) in postmenopausal women that had been treated with Denosumab for 2 years.<sup>45</sup> While Denosumab has been shown to be a safe therapy choice, there is a possible side effect that might need further correlation study called frozen bone process. Complete inhibition of bone remodeling process leads to increment of microfractures thus increasing the risk of atypical femoral fracture called the frozen bone process.<sup>7</sup>

## **Natural Resources as Bone Resorption Inhibitor**

Evidence in studies proved that natural sources including herbal products could participate in these processes thus giving beneficial factors to bone's well-being. A group of vegetables consists of onion, garlic and parsley was reported to have the ability to inhibit bone resorption in ovariectomized rats. Essential oils are taken from thyme, sage, rosemary and other herbs inhibit osteoclast activity thus increasing bone mineral density. Soya bean, usually known for its rich source of isoflavones has shown promising results to use as a therapeutic agent in maintaining bone health.<sup>3</sup>

On a more specific level, caffeic acid (3,4-dihydroxycinnamic acids) is a molecule found on a variety of plants, one of which is yam that has an inhibitory effect towards osteoclastogenesis by inhibiting NFκB.<sup>4,46</sup> It's derivative, caffeic acid phenethyl ester (CAPE) has been shown to have anti-inflammatory component and suppresses osteoclastogenesis. CAPE significantly inhibited osteoclast formation induced by RANKL and proposed as a therapeutic agent for bone related diseases.<sup>47</sup>

### **Onion**

Onion (*Allium cepa*) is a species member of *Allium* genus and is a widely used food ingredient. Its beneficial properties have been studied, and evidence showed that onion inhibited bone resorption in rats in a dose dependant manner.<sup>48</sup> Onion powder solution was reported to inhibit osteoclastogenesis by inhibiting RANKL-induced ERK, p38 MAPK, and NFκB activation but did not affect the differentiation and maturation of cultured osteoblasts. Current studies' data suggest that onion enriched diet might be beneficial to bone's health and prevent bone loss related diseases.<sup>49</sup>

### **Caffeic acid**

Caffeic acid is one of hydroxycinnamic acids found in green plants and food sources such as berries, potatoes, coffee, carrots and sweet potato that has been studied by scientists to evaluate its beneficial properties.<sup>4,50</sup> Caffeic acid is a natural resource that has many uses as a therapeutic agent, one of which is to inhibit N-Nitrosation *in vitro*, which can prevent the formation of mutagenic and carcinogenic compounds. A study in 2011 showed caffeic acid's significant inhibitory ability towards osteoclastogenesis by suppressing NFκB activity. A detailed mechanism of how caffeic acid inhibits osteoclastogenesis remains unclear.<sup>4</sup> However, a further study explained that caffeic acid did not significantly affect the expression of TRAF 6 while significantly suppressed NFκB's activity in TRAF 6-transfected RANKL-TNF-α-induced RAW-D cells.<sup>51</sup> Apoptotic induction by caffeic acid has also been reported in cancer cells such as SCM1 Gastric, HeLa cervical cancer cells, and lastly, MG-63 osteosarcoma cell line, through a series of caspase activation.<sup>52</sup>

### **CAPE**

CAPE is an active compound found in the extract of propolis collected by bees from several plant species. CAPE fights viruses, works as an anti-inflammatory, anti-mitogenic, anti-carcinogenic, and an effective immunomodulator.<sup>53</sup> It has been shown that CAPE has a positive impact on wound healing and inhibits osteoclastic activity, which benefits new bone formation. CAPE does not have a significant influence on the phosphorylation of p38 MAPK, JNK and ERK in the bone marrow cells of mice and fights bone resorption by suppressing RANKL-induced NFκB/NFATc activity and inducing osteoclast apoptosis.<sup>54,55</sup>

### **Soy isoflavones**

Flavanoids have been reported to enhance bone formation and inhibit bone resorption through various signaling pathways that influence the bone metabolism. Flavanoids can be found in fruits, vegetables, herbs, spices, essential oils, and beverages. Soy isoflavones is a member of the flavanoid family that has been studied for their role in bone health and can be found in soya beans.<sup>56</sup> Soy isoflavones called as daidzain and genistein often found in soybeans have a similar structure to estrogen and have the ability to bind to the estrogen receptor. A study showed that isoflavones might help postmenopausal women to prevent osteoporosis.<sup>57,58</sup> In addition, soy isoflavones suppress osteoclastic activities by working like estrogens, inhibiting c-Fos-induced NFATc1 expression.<sup>59</sup>

### **Other natural resources**

Traditional herbal medicine has been widely used amongst the Chinese and Ayurvedic medical practice.<sup>3</sup> Turmeric root (*Curcuma longa*) for example, a staple ingredient in Chinese and Ayurvedic medical practice has an active ingredient called curcumin that has been proven to prevent osteoclastogenesis while also has anti-inflammatory and antioxidant characteristics.<sup>60</sup> Chinese traditional herbs such as *Herba epimedii* (Yin Yang Huò) and *Fructus psoraleae* (Bǔ Gǔ Zhī) contain components that give similar effects to estrogen that may have the potential to be developed as new phytoestrogens.<sup>61</sup> Other Chinese traditional herbs called *Malva verticillata* showed promising results suppressing osteoclast activities by inhibiting c-Fos, NFATc1, the phosphorylation of c-Jun N-terminal kinase, p38, inhibitor of κBα (IκB)α and phospholipase γ2.<sup>62</sup> *Stewartia koreana*, a natural plant product found in Korea also reported having a strong inhibitory effect on osteoclast formation by suppressing the induction of c-Fos and NFATc1 by RANKL.<sup>5</sup>

### **Conclusion**

Bone resorption process is a complex mechanism that involves various bone metabolism pathways creating mature osteoclast cells. Understanding the mechanisms of bone resorption is one of the keys to treat bone-related diseases. Various treatments have been discovered from synthetic drugs to natural resources. While synthetic drugs are more commonly known for its benefits, it comes with a package of potential side effects. On the other hand, natural

resources might have the potential to treat bone-related diseases without the harming side effects of synthetic drugs, targeting specific aspects of the osteoclastogenesis pathways to provide suiting therapy for bone related diseases.

## References

- Patil CS, Kirkwood KL. MAPK P38 MAPK Signaling in Oral-Related Diseases. *J Dent Res.* 2007; 86(9): 812-25.
- Thouverey C, Caverzasio J. Focus on The P38 MAPK Signaling Pathway in Bone Development and Maintenance. *Bonekey Rep.* 2015; 4: 711. doi: 10.1038/Bonekey.2015.80.
- Putnam SE, Scutt AM, Bicknell K, Priestley CM, Williamson EM. Natural Products as Alternative Treatments for Metabolic Bone Disorders and for Maintenance of Bone Health. *Phytother Res.* 2007; 21(2): 99-112.
- Sandra F, Kukita T, Tang QY, Iijima T. Cafeic Acid Inhibits Nfkappab Activation of Osteoclastogenesis Signaling Pathway. *Indones Biomed J.* 2011; 3(3): 216-22.
- Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, et al. Inhibitory Effects of *Stewartia koreana* on Osteoclast Differentiation and Bone Resorption. *Int Immunopharmacol.* 2007; 7(12): 1507-16.
- Fadanelli ME, Bone HG. Combining Bisphosphonates with Hormone Therapy for Postmenopausal Osteoporosis. *Treat Endocrinol.* 2004; 3(6): 361-9.
- Miyazaki T, Tokimura F, Tanaka S. A Review of Denosumab for The Treatment of Osteoporosis. *Patient Prefer Adherence.* 2014; 8: 463-71.
- Revu S, Neregård P, Klint E, Korotkova M, Catrina AI. Synovial Membrane Immunohistology in Early-Untreated Rheumatoid Arthritis Reveals High Expression of Catabolic Bone Markers That is Modulated by Methotrexate. *Arthritis Res Ther.* 2013; 15(6): 1-10.
- Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, et al. Risedronate Directly Inhibits Osteoclast Differentiation and Inflammatory Bone Loss. *Biol Pharm Bull.* 2009; 32(7): 1193-8.
- Barbato L, Francioni E, Bianchi M, Mascitelli E, Brancato L, Duvina M, et al. Periodontitis and Bone Metabolism. *Clin Cases Miner Bone Metab.* 2015; 12(2): 174-7.
- Gruber R. Cell Biology of Osteoimmunology. *Wien Med Wochenschr.* 2010; 160(17-18): 438-45.
- Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) Binds with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): Suppression of TRAIL-Induced Apoptosis in Ameloblastomas. *Oral Oncol.* 2006; 42(2): 415-20.
- Kukita A, Ichigi Y, Takigawa I, Watanabe T, Kukita T, Miyamoto H. Infection of RANKL-Primed RAW-D Macrophages with *Porphyromonas gingivalis* Promotes Osteoclastogenesis in A TNF- $\alpha$ -Independent Manner. *Plos One.* 2012; 7(6): 1-12. doi:10.1371/Journal.Pone.0038500. E38500.
- Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. *Chonnam Med J.* 2016; 52(1): 12-7.
- Soysa NS, Alles N, Aoki K, Ohya K. Osteoclast Formation and Differentiation: An Overview. *J Med Dent Sci.* 2012; 59(3): 65-74.
- Chambers TJ. Regulation of The Differentiation and Function of Osteoclasts. *J Pathol.* 2000; 192(1): 4-13.
- Boyce BF, Xing L. Functions Of RANKL/RANK/OPG in Bone Modeling and Remodeling. *Arch Biochem Biophys.* 2008; 473(2): 139-46.
- Bell NH. RANK Ligand and The Regulation of Skeletal Remodeling. *J Clin Invest.* 2003; 111(8): 1120-2.
- Boyle WJ, Simonet WS, Lacey DL. Osteoclast Differentiation and Activation. *Nature.* 2003; 423(6937): 337-42.
- Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, et al. Osteoclast Differentiation Independent of The TRANCE-RANK-TRAF6 Axis. *J Exp Med.* 2005; 202(5): 589-95.
- Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, et al. Segregation of TRAF6-Mediated Signaling Pathways Clarifies Its Role in Osteoclastogenesis. *EMBO J.* 2001; 20(6): 1271-80.
- Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, et al. Akt1 in Osteoblasts and Osteoclasts Controls Bone Remodeling. *Plos One.* 2007; 2(10): 1-11.
- Maruotti N, Grano M, Colucci S. Osteoclastogenesis and Arthritis. *Clin Exp Med.* 2011; 11(3): 137-45.
- Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK Signaling in Osteoclastogenesis and Bone Disease. *Trends Mol Med.* 2006; 12(1): 17-25.
- Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, et al. Nfatc1 in Mice Represses Osteoprotegerin During Osteoclastogenesis and Dissociates Systemic Osteopenia From Inflammation in Cherubism. *J Clin Invest.* 2008; 118: 3775-89.
- Walsh MC, Choi Y. Biology Of The RANKL-RANK-OPG System In Immunity, Bone, And Beyond. *Front Immunol.* 2014; 5: 1-11. doi: 10.3389/fimmu.2014.00511.
- Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate C, Mangelsdorf DJ, et al. Bklotho is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism. *Cell Metab.* 2012; 16(3): 387-93.
- Weitzmann MN, Pacifici R. The Role of T Lymphocytes in Bone Metabolism. *Immunol Rev.* 2005; 208: 154-68.
- Wu L, Guo Q, Yang J, Ni B. Tumor Necrosis Factor Alpha Promotes Osteoclast Formation via PI3K/Akt Pathway-Mediated Blimp1 Expression Upregulation. *J Cell Biochem.* 2016; 118(6): 1308-15.
- Koga T, Kodama T, Ochi S, Shinohara M, Sato K, Takai T, et al. Pathological Role of Osteoclast Costimulation in Arthritis-Induced Bone Loss. *PNAS.* 2007; 104(27): 11394-9.
- Faccio R, Takeshita S, Zallone A, Ross F, Teitelbaum S. C-Fms and The  $\text{Av}\beta 3$  Integrin Collaborate During Osteoclast Differentiation. *J Clin Invest.* 2003; 111(5): 749-58.
- Catrina AI, Trollmo C, Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence That Anti-tumor Necrosis Factor Therapy with Both Etanercept and Infliximab Induces Apoptosis in Macrophages, but Not Lymphocytes, in Rheumatoid Arthritis Joints Extended Report. *Arthritis Rheum.* 2005; 52(1): 61-72.
- Pers J, Saraux A, Pierre R, Youinou P. Anti-TNF- $\alpha$  Immunotherapy is Inflammation without Clinical Attachment Loss in Subjects with Rheumatoid Arthritis. *J Periodontol.* 2008; 79(9): 1645-51.
- Yamashita T, Takahashi N, Udagawa N. New Roles of Osteoblasts Involved in Osteoclast Differentiation. 2012; 3(11): 175-81.
- Ross F. M-CSF, C-Fms, and Signaling in Osteoclasts and Their Precursors. *Ann NY Acad Sci.* 2006; 1068(1): 110-6.
- Newton A. Protein Kinase C: Structural and Spatial Regulation by Phosphorylation, Cofactors, and Macromolecular Interactions. *Chem Rev.* 2001; 101(8): 2353-64.
- Russell RGG. Pharmacological Diversity Among Drugs That Inhibit Bone Resorption. *Curr Opin Pharmacol.* 2015; 22: 115-30.

38. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. *Mayo Clin Proc.* 2008; 83(9): 1032-45.
39. Kim YH, Kim G, Baek JH. Inhibitory Action of Bisphosphonates on Bone Resorption Does Not Involve The Regulation Of RANKL and OPG Expression. *Exp Mol Med.* 2002; 34(2): 145-51.
40. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. *Mayo Clin Proc.* 2009; 83(9): 1032-45.
41. Watts NB, Diab DL. Long-Term Use of Bisphosphonates in Osteoporosis. *J Clin Endocrinol Metab.* 2010; 95(4): 1555-65.
42. Kim H, Ha H, Lee J, Jung K, Yang D, Woo KM, *et al.* Trichostatin A Inhibits Osteoclastogenesis and Bone Resorption by Suppressing The Induction of C-Fos By RANKL. *Eur J Pharmacol.* 2009; 623(1-3): 22-9.
43. Yi T, Baek J. Trichostatin A-Mediated Upregulation of P21 Osteoclast Apoptosis. *Exp Mol Med.* 2007; 39(2): 213-21.
44. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, *et al.* Trichostatin A is a Histone Deacetylase Inhibitor with Potent Antitumor Activity Against Breast Cancer *in vivo*. *Clin Cancer Res.* 2001; 7(4): 971-6.
45. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for Treating Rheumatoid Arthritis. *Cochrane Database Syst Rev.* 2014; (6): CD000957. doi: 10.1002/14651858.CD000957.pub2.
46. Deeming GMJ, Collingwood J, Pemberton MN. Methotrexate and Oral Ulceration. *Br Dent J.* 2005; 198(2): 83-5.
47. Lewiecki EM, Miller PD, Mcclung MR, Cohen SB, Bolognese MA, Liu Y, *et al.* Two-Year Treatment with Denosumab (AMG 162) in A Randomized Phase 2 Study of Postmenopausal Women with Low BMD. *Journals Bone Miner Res.* 2007; 22(12): 1832-41.
48. Quan YT, Kukita T, Ushijima Y, Kukita A, Nagata K, Sandra F, *et al.* Regulation of Osteoclastogenesis by Simon Extracts Composed of Caffeic Acid and Related Compounds: Successful Suppression of Bone Destruction Accompanied with Adjuvant-Induced Arthritis in Rats. *Histochem Cell Biol.* 2006; 125(3): 215-25.
49. Ha J, Choi H, Lee Y, Lee ZH, Kim H. International Immunopharmacology Caffeic Acid Phenethyl Ester Inhibits Osteoclastogenesis by Suppressing Nfkb and Downregulating Nfatc1 And C-Fos. *Int Immunopharmacol;* 2009; 9(6): 774-80.
50. Mirabeau TY, Samson ES. Effect of Allium Cepa and Allium Sativum on Some Immunological Cells in Rats. *Afr J Tradit Complement Altern Med.* 2012; 9(3): 374-9.
51. Tang C, Huang T, Chang C, Fu W. Water Solution of Onion Crude Powder Inhibits RANKL-Induced Osteoclastogenesis Through ERK, P38 and Nfkb Pathways. *Osteoporos Int.* 2009; 20(1): 93-103.
52. Silva T, Oliveira C, Borges F. Caffeic Acid Derivatives, Analogs and Applications: A Patent Review. *Expert Opin Ther Patents.* 2014; 24(11): 1257-70.
53. Sandra F, Kukita T, Muta T, Iijima T. Caffeic Acid Inhibited Receptor Activator of Nuclear Factor Kb Ligand (RANKL)-Tumor Necrosis Factor (TNF) A-TNF Receptor Associated Factor (TRAF) 6 Induced Osteoclastogenesis Pathway. *Indones Biomed J.* 2013; 5(3): 173-8.
54. Sandra F, Sidharta MA. Caffeic Acid Induced Apoptosis in MG63 Osteosarcoma Cells Through Activation of Caspases. *Mol Cell Biomed Sci.* 2017; 1(1): 28-33.
55. Kuo Y, Jim W, Su L, Chung C, Lin C. Caffeic Acid Phenethyl Ester is A Potential Therapeutic Agent For Oral Cancer. *Int J Mol Sci.* 2015; 16(5): 10748-66.
56. Ang ESM, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, *et al.* Caffeic Acid Phenethyl Ester, An Active Component of Honeybee Propolis Attenuates Osteoclastogenesis and Bone Resorption via The Suppression of RANKL-Induced Nfkb and NFAT Activity. *J Cell Physiol.* 2009; 221(3): 642-9.
57. Hung MW, Shiao MS, Tsai LC, Chang GG, Chang TC. Apoptotic Effect of Caffeic Acid Phenethyl Ester and Its Ester and Amide Analogues in Human Cervical Cancer ME180 Cells. *Anticancer Res.* 2003; 23(6C): 4773-80.
58. Weaver CM, Alekel L, Ward WE, Ronis MJ. Flavonoid Intake and Bone Health Connie. *J Nutr Gerontol Geriatr.* 2012; 31(3): 239-53.
59. Taku K, Melby MK, Nishi N, Omori T, Kurzer MS. Soy Isoflavones for Osteoporosis: An Evidence-Based Approach. *Maturitas.* 2011; 70(4): 333-8.
60. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens Modulate Binding Response of Estrogen Receptors Alpha and Beta to The Estrogen Response Element. *J Agric Food Chem.* 2003; 51(26): 7632-5.
61. Kariab S, Fox SW. Phytoestrogens Directly Inhibit TNF-A-Induced Bone Resorption in RAW264.7 Cells by Suppressing C-Fos-Induced Nfatc1 Expression. *J Cell Biochem.* 2011; 112(2): 476-87.
62. Bharti AC, Takada Y, Aggarwal BB. Curcumin (Diferuloylmethane) Inhibits Receptor Activator of NF-Kb Ligand-Induced NF-Kb Activation in Osteoclast Precursors and Suppresses Osteoclastogenesis. *J Immunol.* 2004; 172(10): 5940-7.
63. Leung P, Siu W. Herbal Treatment for Osteoporosis: A Current Review. *J Tradit Complement Med.* 2013; 3(2): 82-7.
64. Shim K, Lee C, Yim N, Ha H, Ma JY. A Water Extract of Malva Verticillata Seeds Suppresses Osteoclastogenesis and Bone Resorption Stimulated by RANK Ligand. *BMC Complement Altern Med.* 2016; 16(1): 332. doi: 10.1186/S12906-016-1295-6.